Palisade Bio Welcomes a New Addition to its Clinical Advisory Board
Palisade Bio, Inc. (NASDAQ: PALI) has recently made an exciting announcement regarding the addition of Dr. Brian G. Feagan to its Clinical Advisory Board. As a clinical-stage biopharmaceutical company, Palisade is committed to developing groundbreaking therapies aimed at treating autoimmune, inflammatory, and fibrotic conditions. Dr. Feagan's appointment comes at a pivotal time for the company.
Dr. Feagan's Extensive Background in Gastroenterology
With over three decades of experience, Dr. Feagan is recognized as a leading authority in gastroenterology, specifically concerning Crohn’s disease and ulcerative colitis. His impressive track record includes serving as Principal Investigator in more than 140 large-scale, multi-center randomized controlled trials (RCTs). This wealth of experience provides him with a strong foundation in clinical trial design and execution, which will be instrumental as Palisade advances its innovative treatment options.
Impact on Palisade's Mission and Future Therapies
JD Finley, the Chief Executive Officer of Palisade Bio, expressed his enthusiasm about Dr. Feagan joining their team. He emphasized Dr. Feagan’s comprehensive research background and expertise, which are crucial for the ongoing development of next-generation therapies. The company is particularly focused on PALI-2108, which is aimed at treating ulcerative colitis, and they believe Dr. Feagan's insights will facilitate progress.
Insight from Dr. Feagan
In his own words, Dr. Feagan highlighted the growing demand for oral treatment options that not only show effectiveness but also prove to be safe and well-tolerated. He pointed out that PALI-2108's localized bioactivation could be a game-changer in addressing the challenges associated with systemic drug distribution, which often affects patient tolerability. Dr. Feagan looks forward to collaborating with Palisade Bio to explore strategies for clinical efficacy and advancing this promising treatment candidate, filling a significant gap in the medical landscape.
About Dr. Brian Feagan
Currently, Dr. Feagan holds a professorship at the Schulich School of Medicine & Dentistry, University of Western Ontario, where he continues to share his vast knowledge and experience in gastroenterology. He is also affiliated with the London Health Sciences Centre and serves as Senior Scientific Director of Alimentiv, Inc. His membership in numerous prestigious medical associations and his extensive publication record, which boasts over 480 articles, emphasize his role as a thought leader in the field. His previous positions include Director of Robarts Clinical Trials and Senior Scientific Director at Alimentiv Inc., showcasing his commitment to clinical research.
Palisade Bio's Commitment to Innovation
Palisade Bio remains dedicated to transforming the treatment of autoimmune and inflammatory diseases. The company believes that innovative, targeted therapies play a crucial role in overcoming existing treatment limitations. Their strategy includes leveraging novel therapeutic approaches, such as PALI-2108, to improve patient outcomes and quality of life.
The Role of Clinical Advisory Boards
Clinical advisory boards are essential for biopharmaceutical companies like Palisade Bio. They provide strategic guidance and expert opinions that shape the development of new treatments. By engaging renowned specialists like Dr. Feagan, companies can enhance their understanding of clinical challenges and refine their approaches to address unmet medical needs. This collaboration facilitates robust clinical development pathways and ultimately supports the advancement of future therapies.
Frequently Asked Questions
What is the primary focus of Palisade Bio?
Palisade Bio focuses on developing innovative therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases.
Who is Dr. Brian Feagan?
Dr. Brian Feagan is a notable gastroenterologist with extensive experience in clinical research, particularly in Crohn’s disease and ulcerative colitis.
How will Dr. Feagan contribute to Palisade Bio?
Dr. Feagan will provide valuable expertise in clinical trial design and strategy, particularly for the development of PALI-2108.
What is PALI-2108?
PALI-2108 is a novel therapeutic being developed by Palisade Bio for the treatment of ulcerative colitis, utilizing a mechanism aimed at improving patient comfort.
Why are advisory boards important for biopharmaceutical companies?
Advisory boards offer crucial insights and guidance that help shape clinical development strategies and ensure that new treatments effectively meet patient needs.
